Table 3.

Risk of site-specific cancer in patients with Behçet disease.

Cancer SitesObserved, nExpectedSIR (95% CI)p
Lip, oral, pharynx32.221.35 (0.34–3.68)0.567
Gastrointestinal tract33.390.88 (0.22–2.41)0.902
Liver32.131.41 (0.36–3.83)0.526
Lung31.541.95 (0.50–5.30)0.272
Skin00.220
Female breast83.702.16 (1.004–4.11)0.049*
Female genital organ
  Uterus10.482.08 (0.10–10.27)0.465
  Ovary10.502.00 (0.10–9.86)0.483
  Vagina, labia majora, labia minora, clitoris, vulva00.040
Male genital organ
  Prostate10.333.03 (0.15–14.95)0.325
  Testis10.0616.67 (0.83–82.2)0.060
  Penis, epididymis, scrotum00.010
Bladder10.412.44 (0.12–12.03)0.401
Eye00.010
Brain10.273.70 (0.19–18.27)0.267
Hematological malignancy40.954.21 (1.34–10.16)0.019*
  NHL30.368.33 (2.12–22.68)0.006*
  Leukemia10.254.00 (0.20–19.73)0.248
  • * p < 0.05. Observed: newly diagnosed cancer cases of the BD cohort. Expected: cancer incidence (per 1000 person-yrs) × person-years of BD cohort ÷ 1000. SIR: standardized incidence ratio; NHL: non-Hodgkin lymphoma.